作者：
Matteo,Bellone [1]
;
Marco,Bregni [2]
;
Vincenzo,Bronte [3]
;
Stefano,Ugel [3]
;
Pier Francesco,Ferrucci [4]
;
Massimo,Di Nicola [5]
;
Paola,Nisticò [6]
;
Gaia,Zuccolotto [7]
;
Antonio,Rosato [7]
;
Vincenzo,Russo [8]
;
Antonio,Sica [9]
;
Mario P,Colombo [10]
作者单位：
Unit of Cellular Immunology, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
[1]
Clinical Trial Center, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy.
[2]
Immunology Section, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy.
[3]
Unit of Tumor Biotherapy, Department of Experimental Oncology, I.R.C.C.S. European Institute of Oncology, Milan, Italy.
[4]
Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale Tumori, Milan, Italy.
[5]
Unit Tumor Immunology and Immunotherapy, I.R.C.C.S. Regina Elena National Cancer Institute, Rome, Italy.
[6]
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
[7]
Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
[8]
Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, IRCCS Ospedale San Raffaele, Milan, Italy.
[9]
Molecular Immunology Lab, I.R.C.C.S. Humanitas Clinical and Research Center, Rozzano, MI, Italy.
[10]
Department of Pharmaceutical Sciences, University of Piemonte Orientale "A. Avogadro", Novara, Italy.
[11]
Molecular Immunology Unit, Department of Research, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Via Amadeo 42, 20068, Milan, Italy. mariopaolo.colombo@istitutotumori.mi.it.
[12]
DOI
10.1007/s00262-021-03104-1
PMID
34755203
发布时间
2022-07-11
换一批
换一批
